The IC50 and AUC values of the anti-cancer agents in each F-PDO are shown in Table II. RLUN001 and RLUN023 showed high sensitivity (IC50 <250 nM) to all EGFR inhibitors. We have previously reported that the IC50 values of erlotinib and gefitinib for RLUN021 without EGFR mutations were very high at >20 and 6 µM, respectively .

By demonstrating the robustness of specific IC50 calculation methods and the feasibility of using fewer drug concentrations, this study contributed to the standardization and reliability of PDO-based drug sensitivity assays.

PDO 是从 GC 癌症组织中建立的，并使用 全外显子组测序 进行组织和 PDO 的表征。 通过用 Lut、去甲斑蝥素 (NCTD) 和卡铂 (CP) 处理 PDO 进行 药物敏感性测试。 对 PDO 进行 RNA 测序以阐明 Lut 的抗肿瘤机制，并在三种 GC 细胞系中得到进一步验证。 成功构建了11个PDO，与相应肿瘤的病理生理和遗传变化高度一致。 PDO 的 Lut、NCTD 和 CP 的 IC50 分别为 27.19、23.9 和 37.87 μM。 Lut处理上调GC细胞系中 FOXO3 、 DUSP1 和 CDKN1A 的表达，下调 IL1R1 …

2024年9月30日 · Using these PDO lines and a PDO-derived mini-PDX model, we found that the combination of afatinib and gemcitabine induced synthetic lethality in MET N375S mutant lung cancer. Our study demonstrates that PDOs combined with targeted genomic sequencing can assist providers in making clinical decision.

2025年2月13日 · This study investigated factors influencing the accuracy and reproducibility of drug sensitivity measurements in PDOs, focusing on half-maximal-inhibitory-concentration (IC50) calculation methods...

2021年1月21日 · Numerous studies in large-scale drug screens have been published, testing the efficacy of different drugs by looking at the IC50 of the drugs. A list of these drug screens is presented in Table 1. Using PDO drug screens, researchers can find correlations between genetic alterations and drug responses [4, 6, 33].

2023年6月13日 · After follow-up and comparison of the PDTO drug test and final clinical outcome results, the optimal IC 50 cutoff value for PDTO drug sensitivity was 43.26 μmol/L. This PDTO drug test-defined cutoff value could predict patient response with 75.36% sensitivity, 74.68% specificity, and 75% accuracy.

Patient-derived organoids (PDOs) are a promising technology to support precision medicine initiatives for patients with pancreatic ductal adenocarcinoma (PDAC). PDOs may improve clinical next-generation sequencing (NGS) and enable rapid ex vivo chemotherapeutic screening (pharmacotyping).

2019年5月26日 · PDO response was defined as IC50 < 0.1 × published Cmax of the drug clinically; stable as IC50 between 0.1 to 10 × Cmax. Radiographic response was per RECIST criteria. Results: We enrolled 27 refractory metastatic GI cancer patients (9 colorectal [CRC], 9 pancreas, and 9 biliary tract).

After follow-up and comparison of the PDTO drug test and final clinical outcome results, the optimal IC50 cutoff value for PDTO drug sensitivity was 43.26 μmol/L. This PDTO drug test-defined cutoff value could predict patient response with …